May 23 (Reuters) - Biohaven Pharmaceutical said on Monday a late-stage trial of its drug against a genetic neurological disease failed to meet the primary goal of the study. (Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)
Stock market news
- Stock
- Stock market news
- Economy
- Biohaven's drug for genetic neurological disease fails late-stage study